Who are IL-2 (interleukin 2)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gm-Csf, Interleukin 2, Early receiving G-CSF group, Interferon-Alpha, PUVA (8MOP + UVA) + IFN, vunakizumab and recaticimab..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/il-2-interleukin-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

IL-2 (interleukin 2) — Competitive Intelligence Brief

IL-2 (interleukin 2) (IL-2 (interleukin 2)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine. Area: Oncology, Immunology.

marketed Cytokine IL-2 receptor (IL-2R) Oncology, Immunology Small molecule Live · refreshed every 30 min

Target snapshot

IL-2 (interleukin 2) (IL-2 (interleukin 2)) — King's College London. IL-2 binds to IL-2 receptors on T cells and NK cells, promoting their proliferation, activation, and differentiation to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IL-2 (interleukin 2) TARGET	IL-2 (interleukin 2)	King's College London	marketed	Cytokine	IL-2 receptor (IL-2R)
Gm-Csf	gm-csf	Pfizer	marketed	cytokine	GM-CSF receptor	1991-01-01
Interleukin 2	Interleukin 2	Assistance Publique - Hôpitaux de Paris	marketed	Cytokine immunotherapy	IL-2 receptor (CD25)
Early receiving G-CSF group	Early receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)
PUVA (8MOP + UVA) + IFN	PUVA (8MOP + UVA) + IFN	Madrilenian Group of Cutaneous Lymphomas	marketed	Photochemotherapy + cytokine combination
vunakizumab and recaticimab.	vunakizumab and recaticimab.	Xiangya Hospital of Central South University	marketed	Monoclonal antibody (anti-cytokine)	IL-12/IL-23 p40 subunit (vunakizumab); TNF-α (recaticimab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine class)

Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Centre for Endocrinology and Reproductive Medicine, Italy · 1 drug in this class
Amgen · 1 drug in this class
Orasis Pharmaceuticals Ltd. · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
Sandoz · 1 drug in this class
King's College London · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IL-2 (interleukin 2) — Competitive Intelligence Brief. https://druglandscape.com/ci/il-2-interleukin-2. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab